"The rare condition was also reported in about three out of every 100,000 people who received the vaccine made by AstraZeneca in the United Kingdom. Both vaccines used a modified version of an adenovirus, a type of virus known to cause the common cold, to carry the gene for part of the SARS-CoV-2 virus into human cells. This triggered the immune system to create antibodies against SARS-CoV-2."
"In the latest study, the researchers suggest that when people with a specific gene variant (up to 60% of the population) encounter an adenovirus - either through vaccination or natural infection - their immune system produces antibodies against an adenovirus protein called pVII. For almost everyone, this response is harmless. But the team suggests that a subset of people have a mutation in their antibody-producing"
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) affected about one in 200,000 recipients of the Johnson & Johnson vaccine and about three in 100,000 AstraZeneca recipients. Both vaccines used modified adenovirus vectors to deliver a SARS-CoV-2 gene segment, prompting antibody production. Antibodies in VITT patients attacked the blood-clotting protein platelet factor 4 (PF4). A specific gene variant present in up to 60% of people causes production of antibodies against an adenovirus protein called pVII, which is harmless for most individuals. A subset carries a mutation in antibody-producing cells in which a positively charged lysine (K) is swapped for a negatively charged amino acid, increasing risk of harmful antibody activity.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]